8 results about "Human herpesvirus" patented technology

The invention belongs to the technical field of molecular biology, and particularly relates to an RT-PCR kit for simultaneously detecting multiple human herpes viruses and a using method thereof.The kit comprises RT-PCR primer probes, a buffer solution and Taq enzyme, the primer probes and the buffer solution are fully premixed for loading the Taq enzyme, and the primer probes and the buffer solution are mixed for loading the Taq enzyme. The primer probes comprise forward and reverse amplification primers and detection probes respectively aiming at the human herpes virus type 5, the human herpes virus type 6, the human herpes virus type 7 and the human herpes virus type 8, and the sequences are respectively shown as SEQ ID NO.1-SEQ ID NO.13. The kit disclosed by the invention can be used for rapidly detecting and identifying the four types of human herpes viruses at the same time; the kit has high accuracy, specificity and sensitivity.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.

Provided are human herpesvirus affinity ligands and related compositions including affinity resins.

The present disclosure provides a method of inhibiting telomerase activity to reduce human herpesvirus (e.g., HMCV, EBV, HSV-1, and / or HHV-6 / 7 / 8) replication. The method comprises treating cells with a telomerase inhibitor prior to and after HCMV infection. The telomerase inhibitor may be a pharmaceutical inhibitor such as BIBR1532 or MST312, or an siRNA construct targeting the hTERT catalytic subunit of telomerase. Treatment with the telomerase inhibitor results in reduced viral titer, decreased viral gene expression, and diminished viral protein levels across different temporal phases of herpesvirus infection. The method provides a novel approach for inhibiting herpesvirus replication through targeting of host cell telomerase activity.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.

The present disclosure relates to Epstein-Barr Virus (EBV) (human herpesvirus 4) antigens. Specifically, proteins and uses thereof, and self-amplifying mRNA (sa-mRNA) encoding an EBV antigen and uses thereof. The present disclosure relates to vaccines and therapeutic agents, and production and uses thereof.

The present invention discloses a novel recombinant polypeptide, and methods for stimulating protective or therapeutic immune responses to human herpesvirus. The invention relates to a composition comprising isolated homotrimers of a modified gB polypeptide from human cytomegalovirus (hCMV), wherein the gB polypeptide comprises an immunoglobulin signal peptide, an ex-tracellular domain with furin cleavage site mutations, and / or the intravirion domain, but lacks the transmembrane domain. Also the use thereof and methods of treating and preventing CMV associated disease or CMV infections with said composition.

The invention belongs to the technical field of gene engineering, and particularly relates to application of an MDVgC promoter in construction of a recombinant herpes virus vector vaccine. The heterologous gene expressed by the MDVgC promoter is inserted into the herpes virus, especially turkey herpes virus, Marek's disease virus, porcine pseudorabies virus, bovine herpes virus, duck plague virus, human herpes virus (type 1-8), canine herpes virus or feline herpes virus, and the constructed recombinant herpes virus vector vaccine can efficiently express the heterologous gene and is safe and effective.